AL
NYMX

Airain Ltd’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Airain Ltd’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-19,308
Closed -$66K – 1096
2015
Q3 		$66K Sell
19,308
-34,983
-64% -$81.4K ﹤0.01% 788
2015
Q2 		$72K Buy
+54,291
New +$75.8K ﹤0.01% 830

Other funds holding NYMX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
WP
WMS Partners Towson, Maryland $1.78B AUM 11.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
GG
Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return

Airain Ltd's NYMX Position: Q4 2015 in Review

Airain Ltd sold out of Nymox Pharmaceutical Corp (NYMX) in Q4 2015, closing a stake of 19,308 shares — an estimated $66K sold.

Airain Ltd first reported a position in NYMX in Q2 2015 and held it in 2 quarters. The position peaked at $72K in Q2 2015. 31 funds tracked by Wall St. Rank hold NYMX as of Q4 2015.

  • Airain Ltd reported no remaining Nymox Pharmaceutical Corp position as of Q4 2015 after selling out during the quarter.
  • Airain Ltd sold 19,308 Nymox Pharmaceutical Corp shares in Q4 2015, an estimated $66K.
  • Airain Ltd first reported a position in Nymox Pharmaceutical Corp in Q2 2015 and held it in 2 quarters.
  • Airain Ltd's Nymox Pharmaceutical Corp position peaked at $72K in Q2 2015.
  • 31 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q4 2015.

Based on Airain Ltd's 13F filing for Q4 2015, filed 11 Feb 2016.